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KEY PO INT S
l Robust subtypes of
DLBCL are identified
by model-based
clustering of genetic
mutations in a large
(n 5 928) population-
based cohort.
l With full follow-up
data available for all
sequenced patients,
the prognostic
significance of these
subtypes is identified.
Based on the profile of genetic alterations occurring in tumor samples from selected diffuse
large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies pro-
posed partially overlapping classification systems. Using clustering techniques applied to
targeted sequencing data derived from a large unselected population-based patient co-
hort with full clinical follow-up (n 5 928), we investigated whether molecular subtypes can
be robustly identified usingmethods potentially applicable in routine clinical practice. DNA
extracted from DLBCL tumors diagnosed in patients residing in a catchment population
of ∼4 million (14 centers) were sequenced with a targeted 293-gene hematological-
malignancy panel. Bernoulli mixture-model clustering was applied and the resulting sub-
types analyzed in relation to their clinical characteristics and outcomes. Five molecular
subtypes were resolved, termed MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2,
along with an unclassified group. The subtypes characterized by genetic alterations of
BCL2, NOTCH2, andMYD88 recapitulated recent studies showing good, intermediate, and
poor prognosis, respectively. The SOCS1/SGK1 subtype showed biological overlap with
primary mediastinal B-cell lymphoma and conferred excellent prognosis. Although not identified as a distinct cluster,
NOTCH1 mutation was associated with poor prognosis. The impact of TP53 mutation varied with genomic subtypes,
conferring no effect in the NOTCH2 subtype and poor prognosis in the MYD88 subtype. Our findings confirm the
existence of molecular subtypes of DLBCL, providing evidence that genomic tests have prognostic significance in non-
selected DLBCL patients. The identification of both good and poor risk subtypes in patients treated with R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach,
confirming the need for a consensus classification. (Blood. 2020;135(20):1759-1771)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
non-Hodgkin lymphoma.1-3 Although potentially curable with
immunochemotherapy, refractory or relapsed lymphoma oc-
curs in ;40% of patients. Despite the substantial increase in
biological understanding in recent years, attempts to improve
survival by combining standard therapy with novel targeted
agents have thus far yielded disappointing results, with no
phase 3 trial leading to a change in the accepted standard of
care since the addition of rituximab to cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP) chemo-
therapy in 2002.4 One barrier to the effective use of novel
therapies targeting specific pathways is the biological heteroge-
neity of DLBCL and the likely existence of multiple distinct disease
subtypes. Hence, to permit more accurate targeting in clinical trials,
it is becoming increasingly important to define these subtypes,
permitting stratification that separates patients likely to achieve cure
with R-CHOP alone from high-risk groups that may benefit from
emerging therapies.
Gene expression profiling distinguishes transcriptional subtypes
of DLBCL, including activated B-cell–like (ABC) and germinal
center B-cell–like (GCB) in the cell-of-origin classification, and
more recently, molecular high-grade (MHG).5-8 Genomic studies
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have reported additional heterogeneity9-15; the 3 latest used
whole-exome sequencing to describemolecular subtypes based
on the profile of genetic alterations within each tumor.16-18 Two
of these studies proposed partially overlapping classifications16,17;
these converging conclusions suggest the existence of convincing
molecular subtypes with distinct biology and the potential to guide
therapeutic targeting.
However, several questions remain before a consensus classi-
fication can be implemented in clinical practice. The first relates
to robustness, because it is unclear how variation introduced by
different sequencing platforms, variant calling algorithms, bi-
opsymaterial, andmethods of statistical analysis affect the ability
to resolve genetic subtypes. The second relates to the practi-
calities of implementing a classification in a real-world setting:
the ability to resolve genetic subtypes using panel-based se-
quencing on DNA from both fresh and formalin-fixed, paraffin-
embedded (FFPE) material. Finally, studies conducted to date
have been largely based on specimens and data from clinical
trials and specialist referral center archives, potentially limiting
the generalizability of findings to the patient population as
a whole.
Established with the aim of addressing such questions, the
current report describes results froma genomics study embedded
within a contemporary UK “real-world” population-based patient
cohort. All diagnoses in the catchment population of ;4 million
(14 hospitals) are centrally made at a specialized hematological
oncology reference laboratory.19 Using surplus material archived
at the time of diagnosis, 4244 lymphoid and myeloid tumor
samples have now been sequenced and assessed for somatic
mutations against a pan-hematological malignancy panel of 293
genes; the findings for 928 patients diagnosed with DLBCL are
reported here.
Materials and methods
Patients and procedures
Data are from the UK population-based Haematological Ma-
lignancy Research Network (HMRN; https://www.hmrn.org).19
Initiated in 2004, all diagnoses within HMRN’s boundaries are
made and coded by clinical specialists at a single integrated
hematopathology laboratory, the Haematological Malignancy
Diagnostic Service (www.HMDS.info). Full details of HMRN’s
methods and ethical approvals have been published elsewhere;
ethical approval for HMRN was granted under REC reference
04/Q1205/69 and for the genetic sequencing under 14/WS/
0098.19,20 In brief, covering 14 hospitals and tracking all pa-
tients with hematological malignancies (;2400 per year)
through clinical and national administrative systems (mortality
and morbidity), HMRN’s patient cohort operates under a legal
basis that permits full treatment and outcome data to be
collected from clinical records without explicit consent. The
study cohort for the current report comprised 2358 subjects
newly diagnosed with DLBCL between 1 September 2004 and
31 August 2012 with International Classification of Diseases for
Oncology, Third Edition, codes 9679, 9680, 9688, 9712, and
9735. Of these patients, 928 (39.4%) had suitable diagnostic
material for genetic analysis (supplemental Figure 1, available
on the Blood Web site). All patients were followed up for
mortality until 31 December 2018.
DNA sequencing
DNA was extracted from surplus FFPE material archived at the
time of diagnostic biopsy using the Qiagen QIAamp DNA FFPE
tissue kit (catalog no. 51306). For each sample, 50 to 200 ng of
genomic DNA was sheared by using a Covaris LE220 focused
ultrasonicator (Covaris) to produce 100 to 200 bp fragments.
Indexed libraries were generated by using a modified version of
the SureSelect XT protocol (Agilent Technologies), pooled (16-
plex), and captured with a bespoke set of 120 nt biotinylated
RNA baits (Agilent Technologies); this approach covered 293
genes implicated in hematological malignancy (supplemental
Table 1) using the SureDesign interface (Agilent Technologies)
on default parameters (all coding exons of all genes targeted
with 10 flanking bases at 39 and 59 end of each exon). Capture
libraries were quantified, assessed for size distribution and
quality, and sequenced on Illumina HiSeq 2500 instruments
using 75 base paired-end sequencing according to the manu-
facturer’s instructions. The average read depth across all sam-
ples was 5003 reads per base. Full details of sequencing, variant
calling, and annotation are provided in the supplemental
Methods (section 2.1). Single nucleotide variants and copy
number variants are detailed in supplemental Tables 2 and 3.
Statistical analysis
A total of 117 genetic features occurred in at least 1% of patients;
these features defined binary variables denoting 105 mutations,
4 amplifications, and 8 markers indicating presence of either a
homozygous deletion or mutation (supplemental Table 1). These
117 binary variables were used to identify subgroups of patients
with similar genetic characteristics. Genetic features found in
,1% of cases were not used for clustering.
To identify these genetic subgroups, the data weremodeled as a
finite mixture of Bernoulli distributions, providing a data-driven
probabilistic interpretation of group membership strength.21
The number of identifiable clusters was selected by using the
Akaike Information Criterion (AIC) likelihood penalization
method.
Three additional techniques were used to assess cluster strength
and stability. First, the Integrated Completed Likelihood (ICL)22
was used to determine cluster number; second, cluster stability
under repeated resampling was investigated by consensus
clustering23; and third, the clustering process was restricted to
the homogeneous group of de novo DLBCL not otherwise
specified (NOS) patients treated with R-CHOP (n 5 579). Full
details of this sensitivity analysis are presented in the supple-
mental Methods (sections 2.2-2.4).
Survival analysis was conducted by using the Kaplan-Meier es-
timator and proportional hazards regression, with all patients
followed up for mortality until 31 December 2018. Analyses were
conducted in Stata 15.124 and R 3.5.3,25 using the libraries
flexmix21 and survival.26 Gene expression profiling was available
for a subset of cases from a previous analysis, in which full details
of the methods are provided.7,8 Gene Set Enrichment Analysis
was run using software developed by the Broad Institute.27,28
Pearson’s x2 test was used for assessing differences in propor-
tions, with the Benjamini-Hochberg adjustment for multiple
comparisons. The data used in this study are presented in
supplemental Tables 4 and 6; the R-code is available on Github,
at: https://github.com/ecsg-uoy/DLBCLGenomicSubtyping.
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Results
Genetic substructure of DLBCL
Demographic and clinical characteristics of the study cohort
(N 5 2358) and analysis cohort (n 5 928) are summarized in
Table 1. Although broadly similar to the study cohort as a
whole, those with archivedmaterial of sufficient quality for next-
generation sequencing (analysis cohort) were, on average,
slightly younger (median diagnostic age 68.5 vs 70.0 years),
were more likely to have localized disease (eg, 33% vs 30.5%
stage I/II disease), and were more likely to have been treated
with curative intent (86.5% vs 81.8%).
Individual biopsy samples were associated with a median of
7 driver mutations (supplemental Figure 2). In 49 patients
(5.3%), no genetic abnormality was detected. Genetic alter-
ations stratified according to cell of origin confirmed that when
applied to FFPE material, our sequencing platform and variant
calling strategy identified mutational profiles in close agree-
ment with previous studies (supplemental Figure 2).16-18
Applying the Akaike Information Criterion to determine optimal
cluster number, 5 genomic clusters were identified. These
were named MYD88, BCL2, TET2/SGK1, SOCS1/SGK1, and
NOTCH2, according to the genetic features most enriched in
each cluster, leaving 27% of patients as “not elsewhere classified”
(NEC) (Figure 1). Information on the genetic clusters identified using
the integrated completed likelihood criterion and an assessment of
cluster stability by consensus clustering are presented in the sup-
plemental Methods (sections 2.2 and 2.3; supplemental Figures
3-7; supplemental Table 5).
The MYD88 cluster (n 5 152) was dominated by mutation of
MYD88 (L265P), PIM1, CD79B, and ETV6 and frequent loss of
CDKN2A; the available gene expression data showed that most
belonged to the ABC subtype, with enrichment for signatures
associated with ABC-DLBCL, IRF4, andMYC (Figure 2). To assess
biological features of DLBCL independent of anatomic site of
presentation, we included special site DLBCL in our primary
clustering. However, very similar results were observed when
such cases were excluded and clustering restricted to DLBCL
NOS (supplemental Figure 8). The majority of primary central
nervous system lymphomas (PCNSL), along with primary tes-
ticular and those with breast involvement, clustered within this
group (Table 2). This cluster strongly recapitulates the recently
described MCD16 and C517 subtypes.
The BCL2 cluster (n 5 176) showed frequent mutation of EZH2,
BCL2, CREBBP, TNFRSF14, KMT2D, and MEF2B. The majority
of cases for whom fluorescence in situ hybridization (FISH) was
available (82 of 92) had a t(14:18) BCL2 translocation, and
mutation of BCL2 was strongly correlated with this translocation
(P, .0001). Gene expression revealed a predominance of GCB-
DLBCL but also enrichment for MHG DLBCL (Table 2; Figure 2).
Most cases of transformed follicular lymphoma fell within this
cluster, robustly mapping to the previously described EZB and
C3 clusters.16,17
The SOCS1/SGK1 group (n 5 111) was characterized by mu-
tations, including SOCS1,CD83, SGK1,NFKBIA, HIST1H1E, and
STAT3. Several of these genes, including SOCS1, were known
targets of aberrant somatic hypermutation. This cluster seems to
represent a subdivision of the recently described C4 cluster.17
SOCS1 mutation is a finding shared with primary mediastinal
B-cell lymphoma (PMBCL). The inclusion of cases diagnosed as
PMBCL in our clustering allowed the demonstration that 12 of 20
PMCBL cases clustered in this group along with 98 DLBCL NOS
cases. The latter cases in this cluster showed no pathological
features of PMBCL and were not enriched for mediastinal in-
volvement (supplemental Figure 9). Gene expression profiling
showed that DLBCL NOS cases in this group were pre-
dominantly of GCB origin and enriched for signatures associated
with PMBCL and JAK/STAT signaling, suggesting a degree of
biological similarity to PMBCL29 (Figure 2). Enrichment was also
seen for other genes previously noted to be enriched in PMBCL,
including ITPKB, NFKBIE, and CIITA.30 These results suggest
that PMBCL, a lymphoma with a unique anatomic location,
shares significant molecular overlap with a subset of otherwise
nodal DLBCL, supporting a previous description of non-
mediastinal DLBCL tumors that share biological similarity to
PMBCL.29 This also recapitulates the findings observed for the
relation between PCNSL, primary testicular and primary breast
DLCBL, and the MYD88 group of DLCBL NOS, supporting a
more general overlap between special site lymphomas and
specific molecular subsets of DLBCL NOS.
The TET2/SGK1 (n5 98) cluster was characterized by mutations
including TET2, SGK1, KLHL6, ZFP36L1, BRAF, MAP2K1, and
KRAS. Themutation of multiple components of the ERK pathway
was associated with enrichment of gene expression signatures of
RAS and ERK (Figure 2). Predominantly GCB in origin, these
cases seem to represent a second subdivision of the recently
described C4 cluster.17
A final NOTCH2 cluster (n 5 143) was characterized by muta-
tions including NOTCH2, BCL10, TNFAIP3, CCND3, SPEN,
TMEM30A FAS, and CD70. Our targeted panel did not capture
BCL6 fusion status, although BCL6 rearrangement by using
FISH, where available (317 of 928), confirmed a strong corre-
lation with NOTCH2 mutation (P , .0001). Gene expression
showed that this cluster comprised a mixture of ABC, GCB, and
unclassified DLBCL (Table 2). Enhanced NOTCH activity was not
detected by gene expression, nor could we detect transcrip-
tional evidence of increased NOTCH activity when restricting
analysis to patients with NOTCH2 mutation. The mutational
similarities suggest biological similarity to marginal zone lym-
phoma; a preexisting diagnosis of marginal zone lymphoma was
noted only in 3 patients. This group corresponds closely to the
previously described BN216 or C117 subtypes.
Validation of our clustering strategy on an external
data set
To further explore the relation of clusters defined in our data sets
to those of other cohorts recently defined, we took advantage of
published data from Chapuy et al.17 We considered this from 2
angles: first, by applying our Bernoulli clustering approach to
their total data set; and second, by restricting analysis to the
features in common between our data set and theirs. With re-
spect to the former, our algorithm identified 6 clusters, largely
recapitulating those published by Chapuy et al (supplemental
Figure 10). Genetic features enriched within these clusters
closely matched those enriched in the data of Chapuy et al, as
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Table 1. Patient and tumor characteristics: DLBCL newly diagnosed within HMRN, September 2004 to August 2012
Characteristic Study cohort
Analysis cohort
Total
DLBCL NOS
All patients R-CHOP treated
De novo
R-CHOP treated
All subtypes combined 2358 (100) 928 (100) 839 (100) 609 (100) 579
DLBCL NOS 2170 (92.0) 839 (90.4) – – –
PCNSL 74 (3.1) 33 (3.6) – – –
Primary mediastinal 54 (2.3) 20 (2.2) – – –
T-cell/histiocyte-rich 31 (1.3) 21 (2.3) – – –
Plasmablastic 24 (1.0) 14 (1.5) – – –
Intravascular 5 (0.2) 1 (0.1) – – –
Age at diagnosis (range), y 70.0 (1.6-97.8) 68.5 (8.5-97.8) 68.8 (8.5-97.8) 66.3 (22.8-89.0) 66.1 (22.8-89.0)
Male sex, n (%) 1231 (52.2) 500 (53.9) 451 (53.8) 326 (53.5) 309 (53.4)
Performance status (ECOG)
0-1 1423 (60.3) 588 (63.4) 540 (64.4) 448 (73.6) 448 (77.4)
$2 680 (28.8) 256 (27.6) 219 (26.1) 120 (19.7) 120 (20.7)
Not known* 255 (10.8) 84 (9.1) 80 (9.5) 41 (6.7) 11 (1.9)
Stage (Ann Arbor)
I 337 (14.3) 145 (15.6) 137 (16.3) 111 (18.2) 111 (19.2)
II 383 (16.2) 161 (17.3) 149 (17.8) 139 (22.8) 139 (24.0)
III 313 (13.3) 157 (16.9) 148 (17.6) 124 (20.4) 124 (21.4)
IV 900 (38.2) 321 (34.6) 269 (32.1) 184 (30.2) 184 (31.8)
Not fully staged/not known* 425 (18.0) 144 (15.5) 136 (16.2) 51 (8.4) 21 (3.6)
IPI
Low 445 (20.3) 213 (23.0) 192 (22.9) 178 (29.2) 178 (30.8)
Low/intermediate 365 (16.7) 143 (15.4) 128 (15.3) 110 (18.1) 110 (19.0)
Intermediate/high 394 (18.0) 156 (16.8) 146 (17.4) 116 (19.0) 116 (20.1)
High 462 (19.6) 167 (18.0) 150 (17.9) 95 (15.6) 95 (16.4)
Not known* 692 (29.3) 249 (26.8) 223 (26.6) 110 (18.1) 80 (13.8)
Cell of origin
Classic†
GCB 410 (49.7) 265 (50.5) 252 (52.7) 181 (52.6) 172 (53.6)
ABC 233 (28.2) 142 (27.0) 141 (29.5) 99 (28.8) 91 (28.3)
Unclassified 182 (22.1) 118 (22.5) 85 (17.8) 64 (18.6) 58 (18.1)
Refined†
GCB 359 (43.5) 234 (44.6) 223 (46.7) 163 (47.4) 155 (48.3)
ABC 228 (27.6) 140 (26.7) 139 (29.1) 98 (28.5) 90 (28.0)
MHG 60 (7.3) 34 (6.5) 32 (6.7) 20 (5.8) 19 (5.9)
Unclassified 178 (21.6) 117 (22.3) 84 (17.6) 63 (18.3) 57 (17.8)
Treated curatively 1929 (81.8) 803 (86.5) 730 (87.0) 609 (100.0) 579 (100.0)
R-CHOP treated 1536 (65.1) 648 (69.8) 609 (72.6)
Median survival (95% CI), y 4.1 (3.4-4.9) 6.2 (5.5-7.2) 6.4 (5.6-7.5) 10.2 (8.3-11.9) 10.6 (8.4-12.5)
R-CHOP treated (95% CI), y 9.3 (8.3-10.6) 10.4 (8.4-12.5) 10.2 (8.3-11.9)
5-y OS (95% CI),% 47.7 (45.7-49.7) 54.6 (51.5-57.9) 55.4 (52.1-58.8) 67.3 (63.6-71.1) 68.0 (64.3-71.9)
R-CHOP treated (95% CI), % 62.8 (60.4-65.2) 67.5 (64.0-71.2) 67.3 (63.6-71.1)
Data are presented as n (%) unless otherwise indicated. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; OS, overall survival.
*Includes transformed follicular lymphoma (study cohort, n 5 169; analysis cohort, n 5 55) where baseline information is taken at the time of first diagnosis but not at transformation.
†Percentage of those with material available.
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well as those enriched in clusters within our patient cohort
(supplemental Table 7). However, we were not able to resolve a
division of the SGK1 subgroup, which in our cohort splits into
SOCS1/SGK1 and TET2/SGK1 subgroups, a finding likely to be
explained by the lack of SOCS1 and TET2 mutation calls in the
data of Chapuy et al. Restricting the analysis to the 60 over-
lapping genetic features reproduced 5 of the original subgroups
but led to loss of the cluster defined by TP53 mutation and copy
number alteration (CNA), which corresponded to the C2 cluster
of Chapuy et al (supplemental Figure 11). These cases were
instead predominantly reassigned to the unclassified group
(56%) and the BCL2 group (22.7%). Taken together, these
findings confirm that our clustering approach is robust across
data sets and that the absence of a TP53 cluster in our own
cohort relates to limited copy number information available from
our panel; the majority of cases likely to remain unclassified or
allocated to the BCL2 group.
The clusters found in ourmain analysis are compared in summary
vs those of Chapuy et al17 and Schmitz et al16 in Table 3. A
detailed comparison with Chapuy et al is presented in the
supplemental Methods (section 2.5).
Genomic subtype and patient outcome
Five-year overall survival (OS) estimates for all patients (n5 928)
and those treated with R-CHOP (n 5 648) are presented at the
bottom of Table 2. For all patients, analyses revealed especially
poor outcome for patients in the MYD88 cluster, with 5-year OS
of 42% (34.9-50.7). In contrast, patients within the SOCS1/SGK1,
BCL2, and TET2/SGK1 clusters fared better than patients in the
MYD88 group, with 5-year OS of 64.9% (56.6-74.4), 62.5% (55.7-
70.1), and 60.1% (51.1-70.6), respectively (P , 1023 for each
group compared with MYD88). NEC and NOTCH2 clusters had
intermediate survival: 5-year OS of 53.6% (47.7-60.2) and
48.1% (40.5-57.0) (P 5 .008, .063 compared with MYD88).
To examine survival in a more homogeneous patient cohort, we
restricted our analysis to patients with de novo DLBCL NOS
treated with curative intent (n5 690). Similar survival trends were
observed, with the poorest outcome seen among the MYD88
subgroup (Figure 3A-B; supplemental Figure 12). Because some
of these patients were treated with attenuated regimens that
might be considered “R-CHOP–like,” we repeated the analysis
on the 579 patients with de novo DLBCL treated with R-CHOP
(Figure 3C-D, supplemental Figure 12). Especially good survival
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Figure 1. Heat map of characteristic mutations from each of the 6 genetic clusters that were identified by using the Akaike information criterion in the analysis cohort
(n5 928).Distinct clusters are identified by color. Along the bottom of the figure, the color strip shows the corresponding cell-of-origin classification for each patient. The panel
on the right-hand side shows the enrichment for mutations within each cluster, with a logarithmic q-value scale. Only thosemutations are shown that are identified as significantly
enriched for the given group, as determined by a Benjamini-Hochberg adjusted q, 0.05 from a x2 test of independence. “HD” indicates the homozygous deletion or amutation
in this gene; “noncan” denotes a non-canonical mutation; and “amp” indicates an amplification. For cell-of-origin, UNC represents the unclassified group.
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was seen in SOCS1/SGK1 (n5 84), in which 5-year OSwas 80.2%
(71.5-90.1). However, the apparently negative prognostic im-
pact of MYD88 cluster membership (n 5 78) was reduced, in-
creasing the OS estimate of this subgroup to 62.8% (53.0-74.5);
although not statistically significant (P5 .1), this intriguing result
suggests a specific sensitivity of the MYD88 subtype to either
patient-intrinsic or treatment-related factors that may partially
explain previous controversy regarding its prognostic implication.31
Inspection of clinical risk factors revealed variation across the
molecular cluster; the NOTCH2 group was associated with the
greatest number of patients with high-intermediate and high
International Prognostic Index (IPI) scores (supplemental Figure
13). Figure 3 presents the IPI-adjusted hazard ratios for each
molecular subtype, confirming inferior survival estimates in the
MYD88 subtype, a neutral effect of NOTCH2, and enhanced
survival in the TET2/SGK1, SOCS1/SGK1, and BCL2 groups.
Although our clustering algorithm did not resolve a distinct
NOTCH1 cluster, the majority of NOTCH1 mutant cases were
found within the unclassified NEC group, suggesting they may
represent a distinct subtype too small to be detected by our
modeling strategy. Indeed, the presence of NOTCH1 mutation
(n5 16) conferred an especially poor outcome, with a 5-year OS
of 39% (NOTCH1 mutant vs wild type, P 5 .004) (Figure 4A).
MYC rearrangement was most enriched within the BCL2 cluster
(supplemental Figure 13), conferring poor prognosis in
R-CHOP–treated patients, 5-year OS 50.0% (31.5-79.4), com-
pared vs patients without MYC rearrangement, who had 71%OS
(62.4-81.8) (Figure 4B). Similarly, most cases of double-hit
lymphoma and MHG were found in the BCL2 cluster, where
both conferred a poor prognosis in R-CHOP–treated patients:
5-year OS 43.8% (25.1, 76.3) and 44.4% (21.4, 92.3), respec-
tively. There were insufficient numbers of events to determine
the effect ofMYC rearrangement, double hit lymphoma, orMHG
in other clusters (supplemental Figure 13). Also strongly enriched
within the BCL2 cluster were cases of transformed follicular
lymphoma and cases of DLBCL with a concurrent diagnosis of
follicular lymphoma detected based on results of the diagnostic
A
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Figure 2. Relations between gene expression profiling and the 6 genetic clusters that were identified by using the Akaike information criterion for the 519 subjects
with available gene expression profiling data. (A) Heat map of a selection of signatures. (B) Highlights of a small number of these that exhibit the strongest trends.
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biopsy. Although patients with transformed follicular lymphoma
had inferior survival estimates, in the BCL2 cluster, no differences
in survival between DLBCL with/without a concurrent diagnosis
of follicular lymphoma was observed. This finding agrees with a
recent study by Wang et al32 (supplemental Figure 14).
As noted earlier, we did not identify a distinct TP53/CNA cluster
in our cohort. The potential for other clusters, in particular the
BCL2 subgroup, to contain cases that might otherwise have
been classified to a TP53 cluster prompted us to examine sur-
vival of each cluster stratified according to TP53 mutation status.
Remarkably, the prognostic impact of TP53 mutation (Figure 4C)
varied considerably across the different molecular subtypes
(Figure 4D). TP53 mutation was associated with a worse prog-
nosis in the NEC and BCL2 subtypes and, although uncommon,
TP53 mutation conferred an extremely poor prognosis in the
MYD88 cluster. In contrast, there was no evidence of a prognostic
effect in patients within the NOTCH2 or SOCS1/SGK1 clusters,
and was rarely detected in the TET2/SGK1 cluster. This finding
suggests that in addition to its presence in a TP53-mutant cluster,
TP53mutation may also be acquired by tumors belonging to other
subgroups and that in this scenario its prognostic effect is
subtype dependent.
Discussion
Based on the genomic profile of individual tumors, our large
population-based study defined 5 molecular DLBCL subtypes,
named MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2,
with each having distinct features in terms of both their biology
and clinical outcome.With prospective tracking of treatment and
outcome in 928 patients with DLBCL (trial and nontrial) diag-
nosed by specialist staff at a single laboratory, we escape the
biases that may result from sequencing archived biopsy collections
Table 2. Characteristics according to AIC cluster: DLBCL diagnosed within HMRN, September 2004 to August 2012
Characteristic
Genetic subtype, n (%)
NEC SOCS1/SGK1 TET2/SGK1 MYD88 BCL2 NOTCH2
All subtypes combined 248 (100) 111 (100) 98 (100) 152 (100) 176 (100) 143 (100)
DLBCL NOS 211 (85.1) 98 (88.3) 91 (92.9) 130 (85.5) 173 (98.3) 136 (95.1)
PCNSL 9 (3.6) 0 (0.0) 1 (1.0) 22 (14.5) 0 (0.0) 1 (0.7)
Primary mediastinal 2 (0.8) 12 (10.8) 0 (0.0) 0 (0.0) 3 (1.7) 3 (2.1)
T-cell/histiocyte-rich 16 (6.5) 1 (0.9) 2 (2.0) 0 (0.0) 0 (0.0) 2 (1.4)
Plasmablastic 9 (3.6) 0 (0.0) 4 (4.1) 0 (0.0) 0 (0.0) 1 (0.7)
Intravascular 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
De novo/transformed
De novo 237 (95.6) 110 (99.1) 93 (94.9) 150 (98.7) 155 (88.1) 135 (94.4)
Transformed* 11 (4.4) 1 (0.9) 5 (5.1) 2 (1.3) 21 (11.9) 8 (5.6)
DLBCL with concurrent FL† 9 (3.6) 10 (9.0) 2 (2.0) 2 (1.3) 47 (26.7) 15 (10.5)
Testicular involvement‡ 4 (2.8) 1 (1.8) 0 (0.0) 21 (26.9) 0 (0.0) 2 (3.1)
Breast involvement‡ 2 (2.5) 0 (0.0) 1 (2.0) 9 (12.9) 1 (1.1) 0 (0.0)
Cell of origin§
Classic
GCB 43 (30.3) 56 (86.2) 33 (66.0) 5 (8.2) 92 (82.1) 36 (37.9)
ABC 38 (26.8) 4 (6.2) 5 (10.0) 50 (82.0) 3 (2.7) 42 (44.2)
Unclassified 61 (43.0) 5 (7.7) 12 (24.0) 6 (9.8) 17 (15.2) 17 (17.9)
Refined
GCB 36 (25.4) 51 (78.5) 31 (62.0) 5 (8.2) 78 (69.6) 33 (34.7)
ABC 38 (26.8) 4 (6.2) 5 (10.0) 49 (80.3) 3 (2.7) 41 (43.2)
MHG 7 (4.9) 5 (7.7) 2 (4.0) 1 (1.6) 15 (13.4) 4 (4.2)
Unclassified 61 (43.0) 5 (7.7) 12 (24.0) 6 (9.8) 16 (14.3) 17 (17.9)
Age at diagnosis (range), y 67.0 (12.1-95.2) 66.8 (13.5-97.8) 72.7 (22.8-92.0) 70.2 (35.1-97.4) 66.4 (24.1-88.8) 70.2 (8.5-95.8)
R-CHOP treated 172 (69.4) 85 (76.6) 70 (71.4) 80 (52.6) 141 (80.1) 100 (69.9)
5-y OS (%, 95% CI) 53.6 (47.7-60.2) 64.9 (56.6-74.4) 60.1 (51.1-70.6) 42.1 (34.9-50.7) 62.5 (55.7-70.1) 48.1 (40.5-57.0)
R-CHOP treated (%, 95% CI) 65.6 (58.9-73.1) 80.0 (71.9-89.0) 69.8 (59.8-81.5) 63.8 (54.0-75.2) 69.5 (62.3-77.5) 58.8 (49.8-69.3)
Data are presented as n (%) unless otherwise indicated. AIC, Akaike information criterion; CI, confidence interval; FL, follicular lymphoma; OS, overall survival.
*Prior diagnosis: 22 FLs, 14 marginal zone lymphomas, 7 chronic lymphocytic leukemias, 2 hairy cell leukemias, and 3 Hodgkin lymphomas.
†Includes FL discovered at time of DLBCL diagnosis, excluding those with prior FL diagnosis.
‡Sex-specific proportions.
§Percentage of those with material available.
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Table 3. Comparison of main clusters
Current study Chapuy et al17 Schmitz et al16 Notes
MYD88 C5 MCD Strongly associated with ABC-type
DLBCL. The most robust group,
occurring in all reports. Contains the
majority of cases with PCNSL and
primary testicular lymphoma.
Associated with a poor prognosis
MYD88, PIM1, CD79B, ETV6, CDKN2A CD79B, MYD88, ETV6, PIM1, TBL1XR1 MYD88, CD79B
BCL2 C3 EZB Strongly associated with GCB-type
DLBCL. Mutational profile is shared
with follicular lymphoma. Contains
the majority of cases of transformed
follicular lymphoma and cases with a
concurrent diagnosis of follicular
lymphoma. Generally favorable
prognosis, although enriched for
cases of double-hit lymphoma and
MHG
EZH2, BCL2, CREBBP, TNFRSF14,
KMT2D
BCL2, CREBBP2, EZH2, KMT2D,
TNFRSF14
BCL2 translocation, EZH2
SOCS1/SGK1 C4 Predominantly GCB-type DLBCL.
Shares genetic and gene expression
features of PMBCL. Associated with
the most favorable prognosis
SOCS1, CD83, SGK1, NFKBIA,
HIST1H1E
SGK1, HIST1H1E, NFKBIE, BRAF,
CD83
TET2/SGK1 A less strongly identifiable subtype
emerging from SGK1 when
applying the Akaike information
criterion (supplemental Methods).
Has very strong similarity to SOCS1/
SGK1 but differentiated by the
addition of TET2 and BRAF and the
lack of SOCS1 and CD83.
Associated with a favorable
prognosis
TET2, BRAF, SGK1, KLHL6, ID3
NOTCH2 C1 BN2 Not associated with any cell of origin.
Shares mutational similarity to MZL
but not enriched for cases of
transformed MZL. Less strongly
defined than other subgroups
(supplemental Methods)
NOTCH2, BCL10, TNFAIP3, CCND3,
SPEN
BCL6 translocation, BCL10, TNFAIP3,
UBE2A, CD70
BCL6 translocation,
NOTCH2
NEC Other A default category, containing cases
that could not be classified
elsewhere. Contains cases with no
detected mutation. Likely to also
contain cases belonging to both
NOTCH1 and TP53/CNA
subgroups. Even though 3
abnormalities are significantly
enriched in this group, their q-values
are far less extreme than those of
characteristic mutations from the
other subtypes
NOTCH1, REL amplification, TP53
C2 Characterized by TP53 mutation and
widespread copy number changes.
Due to limited CNA in our study,
these cases were predominantly
allocated to the NEC group
TP53, frequent deletions
C0 Cases with no detectable mutation
were allocated to the NEC groupNo detected abnormalities
N1 Characterized by NOTCH1 mutation,
this was significantly elevated in our
NEC group but only mutated in
2.5% of samples. Associated with
poor outcome
NOTCH1
MZL, marginal zone lymphoma.
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established from the selective referral of clinically or diagnostically
challenging cases to specialist pathology centers. Indeed, the only
determinant of whether patients were included in the analysis
cohort was the availability of sufficient sample for the extraction of
adequate DNA. This unselected cohort therefore provides a
unique representation of real-worldDLBCL thatmay not have been
captured in previous molecular subtyping studies. We have not
restricted the cluster analysis to any particular subtype of DLBCL,
considering an a priori approach to the evolving classification of
these possibly heterogeneous disease types a particular strength of
this study.
Considerable variability in genomic subtype identification can
be introduced by differences in biopsy type, sequencing strat-
egy, variant calling pipeline, driver annotation algorithms, and
the statistical method used to identify genomic clusters. It
remained uncertain whether the genomic clusters described in
recent studies represented sufficiently robust entities to be re-
solved against variation in each of the aforementioned factors.
We used alternative, but widely accepted, pipelines for variant
and driver annotation and different approaches to the identifi-
cation of genomic clusters. Despite these considerable differ-
ences, we have independently converged on very similar
genomic subtypes. Indeed, when comparing enriched muta-
tions between equivalent clusters across studies, we observe a
very high degree of overlap. Therefore, our data strongly sup-
port the conclusion that DLBCL exists as molecularly distinct
subtypes that are resolvable through genomic analysis. Impor-
tantly, wewere able to identify these subtypes by using a targeted
sequencing panel applied to biopsy material, a strategy that
would be applicable to a nonacademic diagnostic laboratory.
The lack of BCL6 fusion data is a limitation of our study. How-
ever, available FISH data confirmed the association between
NOTCH2 mutation and rearrangement of BCL6. Furthermore,
even in the absence of BCL6 fusion data, wewere able to identify
a NOTCH2 subtype that shows mutation enrichment similar to
the previously identified BN2/C116,17 clusters. Our study was also
limited by the extent of copy number data available from our
panel. As such, we did not resolve a subgroup mapping to the
C2 cluster of Chapuy et al.17 The application of our clustering
algorithm to the data of Chapuy et al, applying all or just
overlapping genetic features, supports the existence of this
subtype and the requirement for adequate copy number in-
formation for its detection. Future sequencing panels designed
to assign DLBCL molecular subtype will likely include probes
that target regions of recurrent copy number variability. The
existence of a TP53/CNA cluster is further supported by the
finding that the majority (56%) of these cases were not alter-
natively classified but rather assigned to an unclassified
NEC group according to our cluster algorithm (supplemental
Figure 11). However, 23% of the TP53/CNA cases carried a
mutational profile that, in the absence of copy number data,
reassigns them to the BCL2 cluster. This leads us to hypothesize
that TP53 mutation and associated CNAs may arise in 2 different
contexts: either as the primary determinant of a distinct disease
subtype or alternatively as a secondary event in a tumor arising
fromoneof the other subgroups,most commonly the BCL2 cluster.
A novel finding in our study was the division of the previously
identified SGK1 cluster17 into SOCS1/SGK1 and TET2/SGK1
subgroups, the biological validity of which was supported by the
enrichment of JAK/STAT and ERK gene expression signatures,
respectively. Driver mutations of TET2 and SOCS1 were not
reported in the earlier study,17 which impaired the ability of our
clustering algorithm to resolve this split within the data of
Chapuy et al. These differences in mutation calling, likely due to
differences in variant and driver annotation strategies, highlight
some of the challenges to be overcome when implementing a
consensus classification system. Interestingly, our SOCS1/SGK1
subtype shared both mutation and gene expression profile
similarities with PMBCL, supporting a previous description of
non-mediastinal DLBCL tumors that share biological similarity
with PMBCL.29 This analysis also has parallels with other subsets
of special site lymphomas, including PCNSL and those occurring
de novo in testis and breast, which overlap with the MYD88
subgroup; this finding highlights a recurrent link between special
site and nodal DLBCL NOS across several molecular subsets.
Prospective clinical data on all cases (supplemental Table 4)
provided greater insight into the prognostic impact of clusters,
revealing how survival of MYD88 clustered patients was espe-
cially sensitive to either patient-intrinsic or treatment-related
characteristics. This difference in outcome when analysis of
MYD88 patients is restricted to those treated with full R-CHOP vs
other R-CHOP–like regimens may explain some of the contro-
versy around the prognostic impact of this group.31 Multivariate
analysis allowed us to quantify the relative risk of individual
subtypes independent of IPI factors, an analysis that reinforced
the importance of clinical risk factors in determining prognosis.
Most notably, we have revealed the extremely favorable out-
come of patients in the SOCS1/SGK1 subtype, suggesting this
group might be the subject of future trials examining de-
escalation of therapy.
The large size of our cohort allowed us to examine the impact of
individual factors within clusters. Of particular interest, we were
able to comment on the survival of patients in the BCL2 cluster
with and without concurrent follicular lymphoma according to
results of the diagnostic biopsy. The similarity of survival in re-
sponse to R-CHOP mirrors that recently reported32 and leads us
to hypothesize that DLBCL with concurrent follicular lymphoma
may represent an entity that is biologically and clinically in-
distinguishable from other DLBCL patients clustered into the
BCL2 subgroup, with the finding of concurrent follicular lym-
phoma dependent solely on the region of tumor captured by the
biopsy finding. Conversely, transformed follicular lymphomawas
associated with inferior survival, consistent with this form rep-
resenting a distinct clinical entity.
Individual genetic features allowed us to identify other high-risk
groups. Although we did not identify a distinctNOTCH1 cluster,
the predominance of NOTCH1 mutant cases within the NEC
group and their especially poor outcome support the concept
that these patients should be considered separately in clinical
practice. Many (27 of 66) translocated lymphomas, and the
majority (21 of 38) of double-hit lymphomas, were classified into
the BCL2 cluster, allowing very good and poor risk subgroups to
be resolved from this cluster. Finally, we observe intriguing
variation of the impact of TP53 mutation across clusters with no
detectable effect in the NOTCH2 group, contrasting with the
dismal prognosis conferred in the MYD88 cluster. Overall, this
suggests that individual prognostic information may ultimately
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Figure 3. Survival in clusters identified by using the Akaike information criterion. (A) OS of the 690 patients treated with curative intent stratified according to cluster. (B) OS
of the 579 de novo DLBCL NOS patients treated using R-CHOP, stratified according to cluster. (C) Progression-free survival of the 690 patients treated with curative intent
stratified according to cluster. (D) Progression-free survival of the 579 de novo DLBCL NOS patients treated by using R-CHOP, stratified according to cluster. (E) Crude hazard
ratios of cluster membership for the 579 de novo DLBCL NOS R-CHOP–treated patients. (F) Adjusted hazard ratios of the subset of the group of 579 patients with IPI data
available (n 5 499). CI, confidence interval.
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be best tailored to patients through the combined use of ge-
nomic cluster and individual gene data.
This study is the first to analyze the genetic structure of DLBCL by
using a large unselected population-based register of patients
with full clinical follow-up. Our findings substantiate the con-
clusions of recent studies by confirming the existence of re-
producible molecular subtypes of DLBCL defined by their profile
of genomic alterations. We show that genetic subtypes can be
resolved by using a targeted sequencing panel applied to bi-
opsymaterial acquired in routine clinical practice.We refined the
molecular classification further to identify a new, very good risk
subtype that shares biological features of PMBCL. We also
provide greater insight into the prognostic impact of the ge-
nomic subtypes and their interaction with other genetic and
clinical factors. Together with previous studies, these findings
suggest that the field is ready for a concerted effort to stan-
dardize the molecular subclassification of DLBCL. Stratification
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Figure 4. OS of the de novo DLBCL NOS R-CHOP–treated patients (n 5 579), stratified according to a selection of genetic features. (A) NOTCH1 mutation. (B) MYC
rearrangement status in the subset of patients belonging to the BCL2 Akaike information criterion subtype. (C) TP53 mutation or homozygous deletion. (D) The effect of TP53
mutation or homozygous deletion in each genetic subtype.
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according to molecular subtype will guide the design and in-
terpretation of future clinical trials in DLBCL.
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